Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15845072 | 0.96 | PTPN1 (0.44) | RAB9AMEN1NPC1POLBGAA | |
| SCHEMBL15844488 | 0.96 | PTPN1 (0.44) | RAB9AMEN1NPC1POLBGAA | |
| SCHEMBL11884237 | 0.89 | ALDH1A1 (0.40) | RAB9AMEN1NPC1KMT2AALDH1A1 | |
| SCHEMBL22845855 | 0.79 | GSK3B (0.42) | RAB9AMEN1NPC1POLBGAA | |
| SCHEMBL28085412 | 0.78 | PTPN1 (0.40) | PTPN1 | |
| SCHEMBL28240950 | 0.78 | PTPN1 (0.40) | PTPN1 | |
| SCHEMBL8365427 | 0.78 | ALDH1A1 (0.58) | RAB9AMEN1NPC1POLBGAA | |
| SCHEMBL877438 | 0.77 | HTR2A (0.56) | — | |
| SCHEMBL30006748 | 0.76 | PTPN1 (0.44) | PTPN1 | |
| SCHEMBL6060915 | 0.75 | HTR2A (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114737210-B | Method for continuously preparing 1,3-indenone spiro imidazoline compound by using electrochemical microchannel reaction device | 南京工业大学 | 2023-04-18 | — | — | CN | claimed |
| CN-114737210-A | Method for continuously preparing 1, 3-indene diketone spiroimidazoline compound by using electrochemical microchannel reaction device | 南京工业大学 | 2022-07-12 | — | — | CN | claimed |
| JP-60130521-A | — | — | None | — | — | JP | disclosed |
| JP-60130569-A | — | — | None | — | — | JP | disclosed |
| EP-3611158-B1 | 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2023-12-20 | — | — | EP | disclosed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| EP-3986420-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | Mitopower LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC | 2020-12-24 | — | — | US | disclosed |
| WO-2020257283-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | MITOPOWER LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-2722322-B1 | 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2019-06-12 | — | — | EP | disclosed |
| US-9796753-B2 | N-substituted indenoisoquinolines and syntheses thereof | PURDUE RESEARCH FOUNDATION (US) | 2017-10-24 | — | — | US | disclosed |
| JP-S60130521-A | ANTICANCER AGENT | MORISHITA SEIYAKU KK | 1985-07-12 | — | — | JP | disclosed |
| EP-0138272-A1 | Diarylindane-1,3-diones, their preparation and use | AKZO N.V. (NL) | 1985-04-24 | — | — | EP | disclosed |
| EP-0138272-A1 | Diarylindane-1,3-diones, their preparation and use | AKZO N.V. (NL) | 1985-04-24 | — | — | EP | disclosed |
| EP-0008540-B1 | 2-ARYL-1,3-INDANDIONE DERIVATIVES AND COMPOSITIONS COMPRISING THEM FOR CONTROLLING ECTOPARASITIC ACARINA | UNION CARBIDE CORPORATION (US) | 1984-10-24 | — | — | EP | disclosed |
| US-4386086-A | ENOL DERIVATIVES OF 2-ARYL-1,3-INDANDIONES | UNION CARBIDE CORPORATION (US) | 1983-05-31 | — | — | US | disclosed |
| US-4338122-A | MITICIDES, HERBICIDES | UNION CARBIDE CORPORATION (US) | 1982-07-06 | — | — | US | disclosed |
| US-4260776-A | PYRAZOLONE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-07 | — | — | US | disclosed |
| EP-0008540-A2 | 2-aryl-1,3-indandione derivatives and compositions comprising them for controlling ectoparasitic acarina | UNION CARBIDE CORPORATION (US) | 1980-03-05 | — | — | EP | disclosed |
| EP-0008540-A2 | 2-aryl-1,3-indandione derivatives and compositions comprising them for controlling ectoparasitic acarina | UNION CARBIDE CORPORATION (US) | 1980-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397807-A1 | NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES | NADK, NNT, NAMPT | RAB9A 1616/4885MEN1 3810/4885NPC1 798/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | RAB9A 1616/4885MEN1 3810/4885NPC1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.